Chemo with immunotherapy and targeted drugs for bile duct cancer
Part of Cancer clinical trials.
This trial tests whether adding immunotherapy and targeted therapy to standard chemotherapy can help treat intrahepatic cholangiocarcinoma (a type of bile duct cancer). It is for patients who are starting treatment with one of two specific chemo regimens, possibly combined with the new drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with intrahepatic cholangiocarcinoma (a cancer inside the liver's bile ducts).
- You are starting treatment with either GP or GEMOX chemotherapy.
- Your treatment plan may also include a PD-1 or PD-L1 inhibitor (an immunotherapy) and a TKI inhibitor (a targeted therapy).
- You are not having surgery to remove the tumor right away.
- You are not receiving other local treatments like radiation, radiofrequency ablation, or TACE (chemoembolization).
- Your treatment does not include other combinations of therapies not listed here.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests a new combination of immunotherapy (tislelizumab), radiation, and chemotherapy before surgery for people with bile duct cancer that is hard to remove. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
This trial tests whether combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) can help people with intrahepatic bile duct cancer that hasn't been treated before. It aims to see if this triple approach is safe and effective.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.